Table 3.
Tumor response and prognosis of EGFR mutation and HER2 overexpression to gefitinib
| Marker | N/% | OR (%) | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|
| EGFR+ | 12/10.81 | 10/83.33 | 10.0±1.5 | 27.3±2.9 |
| EGFR- | 99/89.19 | 9/9.09 | 3.8±1.4 | 19.1±4.7 |
| P | 0.000 | 0.000 | 0.000 | |
| HER2+ | 24/21.62 | 7/29.17 | 4.7±1.2 | 20.5±2.4 |
| HER2- | 87/78.38 | 12/13.80 | 3.9±1.6 | 19.2±2.6 |
| P | 0.121 | 0.085 | 0.094 | |
| EGFR+/HER2+ | 6/5.41 | 5/83.33 | 10.3±1.3 | 28.1±3.1 |
| EGFR+/HER2- | 6/5.41 | 5/83.33 | 9.4±1.5 | 26.5±2.7 |
| P | 1.000 | 0.991 | 0.893 | |
| EGFR-/HER2+ | 18/16.22 | 2/11.11 | 4.5±1.3 | 20.2±5.3 |
| EGFR-/HER2- | 81/72.97 | 7/8.64 | 3.8±1.1 | 18.9±3.7 |
| P | 0.667 | 0.732 | 0.000 |
Note: OR Objective response; PFS Median progression free time; OS Overall survival.